105 related articles for article (PubMed ID: 24411971)
1. Progressive cerebellar ataxia and new-onset diabetes.
Kong MF; Glibert G; Baleanu F; Karmali R
Lancet; 2014 Jan; 383(9912):186. PubMed ID: 24411971
[No Abstract] [Full Text] [Related]
2. Auto-immune cerebellar ataxia with anti-GAD antibodies accompanied by de novo late-onset type 1 diabetes mellitus.
Bayreuther C; Hieronimus S; Ferrari P; Thomas P; Lebrun C
Diabetes Metab; 2008 Sep; 34(4 Pt 1):386-8. PubMed ID: 18583169
[TBL] [Abstract][Full Text] [Related]
3. Clinico-pathological findings in a patient with progressive cerebellar ataxia, autoimmune polyendocrine syndrome, hepatocellular carcinoma and anti-GAD autoantibodies.
Piccolo G; Tavazzi E; Cavallaro T; Romani A; Scelsi R; Martino G
J Neurol Sci; 2010 Mar; 290(1-2):148-9. PubMed ID: 20056249
[TBL] [Abstract][Full Text] [Related]
4. A patient with type 1 diabetes mellitus and cerebellar ataxia associated with high titer of circulating anti-glutamic acid decarboxylase antibodies.
Iwasaki H; Sato R; Shichiri M; Hirata Y
Endocr J; 2001 Apr; 48(2):261-8. PubMed ID: 11456277
[TBL] [Abstract][Full Text] [Related]
5. Refractory generalized seizures and cerebellar ataxia associated with anti-GAD antibodies responsive to immunosuppressive treatment.
Nociti V; Frisullo G; Tartaglione T; Patanella AK; Iorio R; Tonali PA; Batocchi AP
Eur J Neurol; 2010 Jan; 17(1):e5. PubMed ID: 19906270
[No Abstract] [Full Text] [Related]
6. High Titer of Circulating Antiglutamic Acid Decarboxylase Antibodies in a Patient with Cerebellar Ataxia and Type 1 Diabetes.
Kataria R; Fernandes S; Lebastchi J; Bravo CA; Sena KN
Conn Med; 2017 Mar; 81(3):161-164. PubMed ID: 29772159
[TBL] [Abstract][Full Text] [Related]
7. Anti-GAD positive stiff-person syndrome and cerebellar ataxia: two treatable conditions that clinicians should be aware of.
Ferraz HB
Arq Neuropsiquiatr; 2012 Sep; 70(9):655-6. PubMed ID: 22990718
[No Abstract] [Full Text] [Related]
8. Autoimmune cerebellar ataxia with glutamic acid decarboxylase 65 antibodies associated with central vestibular symptoms.
London F; Hadhoum N; Zéphir H; Outteryck O; Vermersch P
Acta Neurol Belg; 2017 Sep; 117(3):775-776. PubMed ID: 27988832
[No Abstract] [Full Text] [Related]
9. Cerebellar ataxia with glutamic acid decarboxylase autoantibodies.
Abele M; Weller M; Mescheriakov S; Bürk K; Dichgans J; Klockgether T
Neurology; 1999 Mar; 52(4):857-9. PubMed ID: 10078741
[TBL] [Abstract][Full Text] [Related]
10. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia.
Takenoshita H; Shizuka-Ikeda M; Mitoma H; Song S; Harigaya Y; Igeta Y; Yaguchi M; Ishida K; Shoji M; Tanaka M; Mizusawa H; Okamoto K
J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):386-9. PubMed ID: 11181864
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin and rituximab for cerebellar ataxia with glutamic acid decarboxylase autoantibodies.
Planche V; Marques A; Ulla M; Ruivard M; Durif F
Cerebellum; 2014 Jun; 13(3):318-22. PubMed ID: 24218114
[TBL] [Abstract][Full Text] [Related]
12. Clinical Reasoning: A 70-year-old woman with acute-onset weakness and progressive hemiataxia.
Schreck KC; Orthmann-Murphy JL; Newsome SD
Neurology; 2016 Nov; 87(22):e264-e268. PubMed ID: 27895250
[No Abstract] [Full Text] [Related]
13. Selective loss of Purkinje cells in a patient with anti-glutamic acid decarboxylase antibody-associated cerebellar ataxia.
Ishida K; Mitoma H; Wada Y; Oka T; Shibahara J; Saito Y; Murayama S; Mizusawa H
J Neurol Neurosurg Psychiatry; 2007 Feb; 78(2):190-2. PubMed ID: 17119008
[TBL] [Abstract][Full Text] [Related]
14. [Clinical relevance of anti-GAD antibody in IDDM and NIDDM].
Takahashi K; Satoh J; Toyota T
Nihon Rinsho; 1997 Nov; 55 Suppl():319-23. PubMed ID: 9434487
[No Abstract] [Full Text] [Related]
15. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.
Saiz A; Blanco Y; Sabater L; González F; Bataller L; Casamitjana R; Ramió-Torrentà L; Graus F
Brain; 2008 Oct; 131(Pt 10):2553-63. PubMed ID: 18687732
[TBL] [Abstract][Full Text] [Related]
16. [Slowly progressive type 1 diabetes mellitus whose anti-GAD antibody showed positive conversion after 9 years interval from the onset of the disease].
Misaki A; Seino H; Yamaguchi H; Sakata Y; Kitagawa M; Yamazaki T; Muto G; Kikuchi H; Abe R
Nihon Naika Gakkai Zasshi; 2002 Mar; 91(3):1028-30. PubMed ID: 11985075
[No Abstract] [Full Text] [Related]
17. Anti-GAD Antibody, Seizures, Cerebellar Ataxias and Vitiligo: A Diagnostic Challenge.
Flores-Cantu H; Camara-Lemarroy CR; Calderon-Hernandez HJ; Zapata-Rivera MA; Villareal-Perez JZ; Villareal-Velazquez HJ
Cerebellum; 2015 Jun; 14(3):375-7. PubMed ID: 25575726
[No Abstract] [Full Text] [Related]
18. [Characteristics of adult-onset diabetes patients with GAD autoantibodies in Japan (Ehime Study)].
Onuma H; Ohsawa H; Makino H
Nihon Rinsho; 2002 Aug; 60 Suppl 8():103-9. PubMed ID: 12355733
[No Abstract] [Full Text] [Related]
19. Autoantibody screening in subacute cerebellar ataxia.
Trivedi R; Mundanthanam G; Amyes E; Lang B; Vincent A
Lancet; 2000 Aug; 356(9229):565-6. PubMed ID: 10950237
[TBL] [Abstract][Full Text] [Related]
20. [Slowly progressive IDDM (SPIDDM)].
Kobayashi T
Nihon Rinsho; 1997 Nov; 55 Suppl():604-7. PubMed ID: 9434535
[No Abstract] [Full Text] [Related]
[Next] [New Search]
